The Dupixent from Sanofi S.A. - asthma control expands to more patients

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-28, 05:31. Details in the imprint.

The Dupixent injection pen lies cool and solid in the hand, its click barely audible before the medicine begins to flow under the skin. For many asthma patients, that quiet moment has become a routine that keeps wheezing nights and emergency visits at bay.

How Dupixent works

Dupixent is a monoclonal antibody that targets the IL-4 and IL-13 pathways, key drivers of type 2 inflammation in asthma and several other chronic conditions. It is co-developed and commercialized by Sanofi and Regeneron and prescribed mainly for patients whose disease is not controlled by standard inhaled therapies.

In asthma, the drug is typically administered every two weeks via a pre-filled syringe or pen, allowing patients to self-inject at home after training from their physician or nurse. Many describe a brief sting, then a mild pressure under the skin as the dose goes in, with the trade-off being fewer exacerbations and more stable breathing over time.

Indications beyond asthma

Beyond asthma, Dupixent has secured approvals for atopic dermatitis, chronic rhinosinusitis with nasal polyps and other type 2 inflammatory diseases in key markets including the European Union and the United States. Regulators have gradually widened the label to cover different age groups and disease severities, turning the brand into a broad franchise rather than a single-disease product.

Dermatologists use it for patients whose eczema covers large parts of the body and does not respond adequately to topical steroids or conventional systemic drugs. For these patients, the feeling of healing skin - less oozing, fewer cracks, reduced itching at night - is often as tangible as the injection sting itself, changing daily routines from constant scratching to quietly wearing cotton shirts again.

Dosing, formats and daily use

Sanofi’s head of specialty care, Paul Hudson, often highlights that Dupixent is designed for chronic, long-term management rather than short rescue use. Patients follow a structured dosing schedule, with weight-based regimens for children and fixed-dose regimens for adults, all set out in the product’s prescribing information and patient guides.

In practice, the pen format has become the favored option among adults because it hides the needle and makes the process feel closer to using a small consumer device than a traditional syringe. The tactile feel is deliberately simple - cap off, pen pressed against the thigh or abdomen, button pressed until a soft click and a slowly counting second hand in the mind before removal.

Competitive landscape

Dupixent competes with other biologics for asthma and atopic dermatitis, but its positioning leans on a consistent efficacy and safety profile over several years of follow-up. Physicians value the growing pool of long-term data, which reinforces the idea of the drug as a stable backbone therapy rather than a short experimental course.

As more competitors arrive, pricing pressure is a realistic theme, particularly from payers seeking cost-effective options. Yet the combination of multi-indication use, wide geographical reach and entrenched prescriber habits gives Sanofi room to defend Dupixent’s role as a central revenue pillar even as negotiations over rebates and access intensify.

Context and Sanofi shares

For Sanofi S.A., Dupixent is one of the key biological products anchoring its specialty medicines portfolio and helping to balance more mature franchises in diabetes and cardiovascular care. The product’s steady uptake across asthma and dermatology segments plays into Sanofi’s narrative of building long-cycle, specialty-driven growth. This bestseller drives the price of Sanofi S.A. shares on Euronext Paris, where the FR0000120578 listing is part of major European indices.

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.

en | FR0000120578 | SANOFI | boerse | 69643724 | bgmi